17.05.2010 • News • Astellas • OSI • Mergers & Acquisitions (M&A)

Astellas CEO Says Seeks to Buy 90% Of OSI Shares

Astellas Pharma, Japan's No.2 drugmaker, seeks to buy at least 90% of shares in U.S. drugmaker OSI Pharmaceuticals with its tender offer, the company's chief executive said on Monday.

"As for how many shares we may obtain, we will carry out the tender offer, targeting 90% or more," Astellas president Masafumi Nogimori told a news conference.

Astellas, Japan's No.2 drugmaker, agreed to buy the U.S. biotech for $4 billion in cash in a sweetened bid that allows it to add OSI's blockbuster cancer drug Tarceva to its line-up.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Top-Feature

most read

Photo
19.03.2025 • News • Innovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.